Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KONG-FREEDOM-I: SAPT vs DAPT in CCS and S-ACS Patients Undergoing PCI With DCB-Only Strategy
NCT07587099Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- May 2026
- Primary completion
- Dec 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial in coronary heart disease (CHD) (2 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoint: Net Adverse Clinical Events at 12 months. Started May 2026; status: recruiting.
02
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT07587099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07587099.